Sacituzumab govitecan demonstrated a longer PFS and OS than single-agent chemotherapy in patients with metastatic TNBC in a phase 3 clinical trial.
At the Great Debates & Updates in Women’s Oncology meeting, Shanu Modi, MD, provided insight on personalized treatments for HER2+ breast cancer.
At the Great Debates & Updates in Women's Oncology meeting, Heather McArthur, MD, MPH, participated in a lively debate about the comprehensive use of immunotherapy for TNBC.
Can trastuzumab deruxtecan be administered in sequence, in both third and fourth line setting, among patients with metastatic HER2+ breast cancer?
The FDA has granted full approval to Trodelvy® (sacituzumab govitecan-hziy) for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
Due to possible cardiac toxicity during Herceptin and pertuzumab treatment in HER2+BC, patient cardiac function is monitored via:
Patients with NHL with intermediate risk for FN maintain that risk even with pegfilgrastim prophylaxis, according to research presented at the NCCN Annual Conference.
Findings from a study presented at the NCCN Virtual Annual Congress found that regular DBHI for RNI-rBC improved lung and liver parameters.
Tucatinib plus letrozole and palbociclib was well-tolerated and active in patients with HR and HER2-positive metastatic breast cancer, according to interim data presented at the SABCS Annual Meeting.